Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide

Cancer Immunology, Immunotherapy

Volumn 60, Issue 11, 2011, Pages 1565-1575

  Sakakibara, Mitsuru ^a   Kanto, Tatsuya ^a   Hayakawa, Michiyo ^a   Kuroda, Shoko ^a   Miyatake, Hideki ^b   Itose, Ichiyo ^c   Miyazaki, Masanori ^a   Kakita, Naruyasu ^a   Higashitani, Koyo ^a   Matsubara, Tokuhiro ^a   Hiramatsu, Naoki ^a   Kasahara, Akinori ^a   Takehara, Tetsuo ^a   Hayashi, Norio ^c  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA POLICE HOSPITAL   (Japan)

^c KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

Cancer; Clinical study; Dendritic cell; Vaccine

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE; PICIBANIL; PROSTANOID;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER STAGING; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DRUG FEVER; DRUG MECHANISM; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; INJECTION SITE ABSCESS; INJECTION SITE INDURATION; MALE; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82355169846     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1051-1     Document Type: Article

References (39)

1. J Hwang JL Marshall 2006 Targeted therapy for colorectal cancer Curr Opin Investig Drugs 7 12 1062 1066 17209523 1:CAS:528:DC%2BD2sXntF2nsw%3D%3D (Pubitemid 44941750)
2. IJM de Vries WJ Lesterhuis NM Scharenborg LPH Engelen DJ Ruiter M-JP Gerritsen S Croockewit CM Britten R Torensma GJ Adema CG Figdor CJA Punt 2003 Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients Clin Cancer Res 9 14 5091 5100 14613986 (Pubitemid 37413557)
3. R Vilella D Benítez J Milà M Lozano R Vilana J Pomes X Tomas J Costa A Vilalta J Malvehy S Puig B Mellado R Martí T Castel 2004 Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate Cancer Immunol Immunother 53 7 651 658 10.1007/s00262-003-0495- 3 14999431 10.1007/s00262-003-0495-3 1:STN:280:DC%2BD2c3ns1WqtA%3D%3D (Pubitemid 38858339)
4. AW Lee T Truong K Bickham J-F Fonteneau M Larsson I Da Silva S Somersan EK Thomas N Bhardwaj 2002 A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy Vaccine 20 Suppl 4 A8 A22 12477423 10.1016/S0264-410X(02)00382-1 1:CAS:528:DC%2BD38XptlSqurk%3D (Pubitemid 35449402)
5. IN Mbawuike K Fujihashi S DiFabio S Kawabata JR McGhee RB Couch H Kiyono 1999 Human interleukin-12 enhances interferon-gamma-producing influenza-specific memory CD8+ cytotoxic T lymphocytes J Infect Dis 180 5 1477 1486 10.1086/315090 10515806 10.1086/315090 1:CAS:528:DyaK1MXnsVKgsrc%3D (Pubitemid 29506448)
6. RS Alli A Khar 2004 Interleukin-12 secreted by mature dendritic cells mediates activation of NK cell function FEBS Lett 559 1-3 71 76 10.1016/S0014-5793(04)00026-2 14960310 10.1016/S0014-5793(04)00026-2 1:CAS:528:DC%2BD2cXhtFCiurs%3D (Pubitemid 38186706)
7. K Dredge JB Marriott SM Todryk AG Dalgleish 2002 Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy Cancer Immunol Immunother 51 10 521 531 10.1007/s00262-002-0309-z 12384803 10.1007/s00262-002- 0309-z 1:CAS:528:DC%2BD38XnvV2ltro%3D (Pubitemid 35232001)
8. Toes RE, Offringa R, Feltkamp MC, Visseren MJ, Schoenberger SP, Melief CJ, Kast WM (1994) Tumor rejection antigens and tumor specific cytotoxic T lymphocytes. Behring Inst Mitt Jul(94):72-86
9. M Sakakibara T Kanto M Inoue A Kaimori T Yakushijin H Miyatake I Itose M Miyazaki N Kuzushita N Hiramatsu T Takehara A Kasahara N Hayashi 2006 Quick generation of fully mature dendritic cells from monocytes with OK432, low-dose prostanoid, and interferon-alpha as potent immune enhancers J Immunother 29 1 67 77 16365602 10.1097/01.cji.0000183093.77687.46 1:CAS:528:DC%2BD2MXhtlagt7nE
10. HS Pandha RJ John J Hutchinson N James M Whelan C Corbishley AG Dalgleish 2004 Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study BJU Int 94 3 412 418 10.1111/j.1464-410X.2004.04922.x 15291878 10.1111/j.1464-410X.2004.04922.x 1:CAS:528:DC%2BD2cXnvVGitb8%3D (Pubitemid 39120190)
11. J Babatz C Röllig B Löbel G Folprecht M Haack H Günther C-H Köhne G Ehninger M Schmitz M Bornhäuser 2006 Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells Cancer immunology, immunotherapy CII 55 3 268 276 10.1007/s00262-005-0021-x 16034561 10.1007/s00262-005-0021-x 1:CAS:528:DC%2BD2MXht1GlsLbN (Pubitemid 41682575)
12. Liu K-J, Wang C-C, Chen L-T, Cheng A-L, Lin D-T, Wu Y-C, Yu W-L, Hung Y-M, Yang H-Y, Juang S-H, Whang-Peng J (2004) Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res 10(8):2645-2651 (Pubitemid 38509137)
13. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
14. U Syrbe J Siveke A Hamann 1999 Th1/Th2 subsets: distinct differences in homing and chemokine receptor expression? Springer Semin Immunopathol 21 3 263 285 10666773 10.1007/BF00812257 1:CAS:528:DyaK1MXnvFekt78%3D (Pubitemid 30011439)
15. F Sallusto D Lenig R Förster M Lipp A Lanzavecchia 1999 Two subsets of memory T lymphocytes with distinct homing potentials and effector functions Nature 401 6754 708 712 10.1038/44385 10537110 10.1038/44385 1:CAS:528:DyaK1MXntVWntrw%3D (Pubitemid 29485217)
16. M Marcusson-Stahl K Cederbrant 2003 A flow-cytometric NK-cytotoxicity assay adapted for use in rat repeated dose toxicity studies Toxicology 193 3 269 279 14599763 10.1016/S0300-483X(03)00302-0 1:CAS:528:DC%2BD3sXos1Khtr8%3D (Pubitemid 37355979)
17. E West R Morgan K Scott A Merrick A Lubenko D Pawson P Selby P Hatfield R Prestwich S Fraser D Eves A Anthoney C Twelves D Beirne P Patel D O'Donnell S Watt M Waller A Dietz P Robinson A Melcher 2009 Clinical grade OK432-activated dendritic cells: in vitro characterization and tracking during intralymphatic delivery J Immunother 32 1 66 78 10.1097/CJI.0b013e31818be071 19307995 10.1097/CJI.0b013e31818be071 1:CAS:528:DC%2BD1cXhsFartrbL
18. SL Clarke GJ Betts A Plant KL Wright TM El-Shanawany R Harrop J Torkington BI Rees GT Williams AM Gallimore AJ Godkin 2006 CD4+ CD25+ FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer PLoS ONE 1 e129 10.1371/journal.pone.0000129 17205133 10.1371/journal.pone.0000129
19. P Correale MS Rotundo MT Del Vecchio C Remondo C Migali C Ginanneschi KY Tsang A Licchetta S Mannucci L Loiacono P Tassone G Francini P Tagliaferri 2010 Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy J Immunother 33 4 435 441 10.1097/CJI.0b013e3181d32f01 20386463 10.1097/CJI.0b013e3181d32f01
20. P Salama M Phillips F Grieu M Morris N Zeps D Joseph C Platell B Iacopetta 2009 Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer J Clin Oncol 27 2 186 192 10.1200/JCO.2008.18.7229 19064967 10.1200/JCO.2008.18.7229
21. AM Wolf D Wolf M Steurer G Gastl E Gunsilius B Grubeck-Loebenstein 2003 Increase of regulatory T cells in the peripheral blood of cancer patients Clin Cancer Res 9 2 606 612 12576425 (Pubitemid 36182591)
22. WJ Lesterhuis IJ De Vries G Schreibelt DH Schuurhuis EH Aarntzen A De Boer NM Scharenborg M Van De Rakt EJ Hesselink CG Figdor GJ Adema CJ Punt 2010 Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients Anticancer Res 30 12 5091 5097 21187495
23. Y Ueda T Itoh N Fuji S Harada H Fujiki K Shimizu A Shiozaki A Iwamoto T Shimizu O Mazda T Kimura Y Sonoda M Taniwaki H Yamagishi 2007 Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy Cancer Immunol Immunother CII 56 3 381 389 10.1007/s00262-006-0197-8 10.1007/s00262-006-0197-8 (Pubitemid 46035906)
24. K Matsuda T Tsunoda H Tanaka Y Umano H Tanimura I Nukaya K Takesako H Yamaue 2004 Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells Cancer Immunol Immunother CII 53 7 609 616 10.1007/s00262-003- 0491-7 10.1007/s00262-003-0491-7 1:CAS:528:DC%2BD2cXksFSit70%3D (Pubitemid 38858334)
25. GK Koski PA Cohen RE Roses S Xu BJ Czerniecki 2008 Reengineering dendritic cell-based anti-cancer vaccines Immunol Rev 222 256 276 10.1111/j.1600-065X.2008.00617.x 18364007 10.1111/j.1600-065X.2008.00617.x 1:CAS:528:DC%2BD1cXlsFejt7g%3D (Pubitemid 351430379)
26. M Dauer V Lam H Arnold J Junkmann R Kiefl C Bauer M Schnurr S Endres A Eigler 2008 Combined use of toll-like receptor agonists and prostaglandin E(2) in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production J Immunol Methods 337 2 97 105 10.1016/j.jim.2008.07.003 18657542 10.1016/j.jim.2008.07.003 1:CAS:528:DC%2BD1cXhtVagsL3N
27. M Dauer B Obermaier J Herten C Haerle K Pohl S Rothenfusser M Schnurr S Endres A Eigler 2003 Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors J Immunol 170 8 4069 4076 12682236 1:CAS:528:DC%2BD3sXisleku70%3D (Pubitemid 36428169)
28. S Anguille ELJM Smits N Cools H Goossens ZN Berneman VFI Van Tendeloo 2009 Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties J Transl Med 7 109 10.1186/1479-5876-7-109 20021667 10.1186/1479-5876-7-109
29. DE Avigan B Vasir DJ George WK Oh MB Atkins DF McDermott PW Kantoff RA Figlin MJ Vasconcelles Y Xu D Kufe RM Bukowski 2007 Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma J Immunother 30 7 749 761 10.1097/CJI.0b013e3180de4ce8 17893567 10.1097/CJI.0b013e3180de4ce8 (Pubitemid 47480758)
30. A Berntsen R Trepiakas L Wenandy PF Geertsen P thor Straten MH Andersen AE Pedersen MH Claesson T Lorentzen JS Johansen IM Svane 2008 Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial J Immunother 31 8 771 780 10.1097/CJI.0b013e3181833818 18779742 10.1097/CJI.0b013e3181833818 1:CAS:528:DC%2BD1cXhtFCrtLzL
31. SK Burgdorf A Fischer PS Myschetzky SB Munksgaard M-B Zocca MH Claesson J Rosenberg 2008 Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine Oncol Rep 20 6 1305 1311 19020707
32. Trepiakas R, Berntsen A, Hadrup SR, Bjørn J, Geertsen PF, Straten PT, Andersen MH, Pedersen AE, Soleimani A, Lorentzen T, Johansen JS, Svane IM (2010) Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy. doi: 10.3109/14653241003774045
33. B Kavanagh A Ko A Venook K Margolin H Zeh M Lotze B Schillinger W Liu Y Lu P Mitsky M Schilling N Bercovici M Loudovaris R Guillermo SM Lee J Bender B Mills L Fong 2007 Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides J Immunother 30 7 762 772 10.1097/CJI.0b013e318133451c 17893568 10.1097/CJI.0b013e318133451c 1:CAS:528:DC%2BD2sXhtVOrtL7I (Pubitemid 47480759)
34. J Babatz C Röllig B Löbel G Folprecht M Haack H Günther C-H Köhne G Ehninger M Schmitz M Bornhäuser 2006 Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells Cancer Immunol Immunother 55 3 268 276 10.1007/s00262-005-0021-x 16034561 10.1007/s00262-005-0021-x 1:CAS:528:DC%2BD2MXht1GlsLbN (Pubitemid 41682575)
35. M Jinushi T Takehara T Kanto T Tatsumi V Groh T Spies T Miyagi T Suzuki Y Sasaki N Hayashi 2003 Critical role of MHC class I-related chain A and B expression on IFN-alpha-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection J Immunol 170 3 1249 1256 12538683 1:CAS:528:DC%2BD3sXnvVOmtA%3D%3D (Pubitemid 36139490)
36. T Osada T Clay A Hobeika HK Lyerly MA Morse 2006 NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity Cancer Immunol Immunother 55 9 1122 1131 10.1007/s00262-005-0089-3 16273350 10.1007/s00262-005-0089-3 (Pubitemid 43800727)
37. K Shimizu S Fujii 2009 DC therapy induces long-term NK reactivity to tumors via host DC Eur J Immunol 39 2 457 468 10.1002/eji.200838794 19180466 10.1002/eji.200838794 1:CAS:528:DC%2BD1MXitlGjsr8%3D
38. R Perret F Ronchese 2008 Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours? Tissue Antigens 72 3 187 194 10.1111/j.1399-0039.2008.01088.x 18627571 10.1111/j.1399-0039.2008.01088.x 1:CAS:528:DC%2BD1cXhtFKrsLnI
39. R Mortarini A Piris A Maurichi A Molla I Bersani A Bono C Bartoli M Santinami C Lombardo F Ravagnani N Cascinelli G Parmiani A Anichini 2003 Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma Cancer Res 63 10 2535 2545 12750277 1:CAS:528:DC%2BD3sXjslehtrw%3D (Pubitemid 36605194)